| HOME >> MEDICINE >> TECHNOLOGY |
Table 31: Tarceva: overview 84
Table 32: Tarceva: sales forecast ($m), 2008-14 85
Table 33: Epogin: overview 87
Table 34: Epogin: sales forecast ($m), 2008-14 88
Table 35: R-744/Mircera: overview 90
Table 36: R-744/Mircera: sales forecast ($m), 2008-14 91
Table 37: Actemra: overview 93
Table 38: Actemra: sales forecast ($m), 2008-14 94
Table 39: Tamiflu: overview 96
Table 40: Tamiflu: sales forecast ($m), 2008-14 97
Table 41: Stockpiling and prescription Tamiflu sales ($m), 2003-08 97
Table 42: Pegasys: overview 98
Table 43: Pegasys: sales forecast ($m), 2008-14 99
Table 44: Evista: overview 102
Table 45: Evista: sales forecast ($m), 2008-14 103
Table 46: R-484/Boniva: overview 105
Table 47: R-484/Bomiva: sales forecast ($m), 2008-14 106
Table 48: Chugai's R&D pipeline (Phase I-registration) 107
Table 49: Exchange rates, 2009 110
List of Figures
Figure 1: The PharmaVitae Explorer 3
Figure 2: Chugai prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 6
Figure 3: Chugai's financial performance ($m), 2002-14 7
Figure 4: Roche/Genentech/Chugai alliance 9
Figure 5: Chugai dependency on mAb portfolio as a % of total revenues, 2002-14 10
Figure 6: Total Japanese mAb market sales by company, 2002-14 ($m) 11
Figure 7: Chugai pharmaceutical sales growth by source company, 2002-14 ($m) 12
Figure 8: Chugai SWOT analysis 14
Figure 9: Current corporate structure 29
Figure 10: Chugai prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 31
Figure 11: Key product sales ($m), 2002-14 33
Figure 12: Chugai key sales growth drivers and resistors ($m), 20
'/>"/>
| SOURCE Reportlinker Copyright©2009 PR Newswire. All rights reserved |